Literature DB >> 28599957

Pulmonary surfactant dysfunction in pediatric cystic fibrosis: Mechanisms and reversal with a lipid-sequestering drug.

Lasantha Gunasekara1, Mustafa Al-Saiedy2, Francis Green3, Ryan Pratt1, Candice Bjornson4, Ailian Yang5, W Michael Schoel6, Ian Mitchell4, Mary Brindle7, Mark Montgomery4, Elizabeth Keys8, John Dennis9, Grishma Shrestha8, Matthias Amrein10.   

Abstract

BACKGROUND: Airway surfactant is impaired in cystic fibrosis (CF) and associated with declines in pulmonary function. We hypothesized that surfactant dysfunction in CF is due to an excess of cholesterol with an interaction with oxidation.
METHODS: Surfactant was extracted from bronchial lavage fluid from children with CF and surface tension, and lipid content, inflammatory cells and microbial flora were determined. Dysfunctional surfactant samples were re-tested with a lipid-sequestering agent, methyl-β-cyclodextrin (MβCD).
RESULTS: CF surfactant samples were unable to sustain a normal low surface tension. MβCD restored surfactant function in a majority of samples.Mechanistic studies showed that the dysfunction was due to a combination of elevated cholesterol and an interaction with oxidized phospholipids and their pro-inflammatory hydrolysis products.
CONCLUSION: We confirm that CF patients have impaired airway surfactant function which could be restored with MβCD. These findings have implications for improving lung function and mitigating inflammation in patients with CF.
Copyright © 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cholesterol, oxidative stress; Cystic fibrosis; Free fatty acids; Genotypes; Infection; Inflammation; Lung surfactant; Phospholipids; Surface tension

Mesh:

Substances:

Year:  2017        PMID: 28599957     DOI: 10.1016/j.jcf.2017.04.015

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  8 in total

1.  Cyclodextrins reduce the ability of Pseudomonas aeruginosa outer-membrane vesicles to reduce CFTR Cl- secretion.

Authors:  Roxanna Barnaby; Katja Koeppen; Bruce A Stanton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-25       Impact factor: 5.464

2.  Surfactant Dysfunction in ARDS and Bronchiolitis is Repaired with Cyclodextrins.

Authors:  Mustafa Al-Saiedy; Lasantha Gunasekara; Francis Green; Ryan Pratt; Andrea Chiu; Ailian Yang; John Dennis; Cora Pieron; Candice Bjornson; Brent Winston; Matthias Amrein
Journal:  Mil Med       Date:  2018-03-01       Impact factor: 1.437

3.  Decreased surfactant lipids correlate with lung function in chronic obstructive pulmonary disease (COPD).

Authors:  Christina W Agudelo; Britta K Kumley; Estela Area-Gomez; Yimeng Xu; Abdoulaye J Dabo; Patrick Geraghty; Michael Campos; Robert Foronjy; Itsaso Garcia-Arcos
Journal:  PLoS One       Date:  2020-02-06       Impact factor: 3.240

Review 4.  Airway Redox Homeostasis and Inflammation Gone Awry: From Molecular Pathogenesis to Emerging Therapeutics in Respiratory Pathology.

Authors:  Javier Checa; Josep M Aran
Journal:  Int J Mol Sci       Date:  2020-12-07       Impact factor: 5.923

Review 5.  Membrane Lipid Composition: Effect on Membrane and Organelle Structure, Function and Compartmentalization and Therapeutic Avenues.

Authors:  Doralicia Casares; Pablo V Escribá; Catalina Ana Rosselló
Journal:  Int J Mol Sci       Date:  2019-05-01       Impact factor: 5.923

Review 6.  The Implications for Cells of the Lipid Switches Driven by Protein-Membrane Interactions and the Development of Membrane Lipid Therapy.

Authors:  Manuel Torres; Catalina Ana Rosselló; Paula Fernández-García; Victoria Lladó; Or Kakhlon; Pablo Vicente Escribá
Journal:  Int J Mol Sci       Date:  2020-03-27       Impact factor: 5.923

Review 7.  Inhaled RNA Therapy: From Promise to Reality.

Authors:  Michael Y T Chow; Yingshan Qiu; Jenny K W Lam
Journal:  Trends Pharmacol Sci       Date:  2020-09-04       Impact factor: 14.819

Review 8.  A recipe for a good clinical pulmonary surfactant.

Authors:  Jesús Pérez-Gil
Journal:  Biomed J       Date:  2022-03-08       Impact factor: 7.892

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.